All Posts
  • Press Releases
1 min read

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

On this page

Share

First clinical data from Phase 1 dose-escalation study in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). TRX103 demonstrated exceptional safety, accelerated immune reconstitution, and dose-dependent persistence and induction of Tr1 and FOXP3+ regulatory T cells. All patients achieved successful engraftment and donor chimerism following transplantation.

Related Articles

Explore posts connected to this topic

View Resources

Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit

San Diego, CA, and Bergisch Gladbach, Germany – September 15, 2026 – Tr1X, Inc. and Miltenyi Biotec today announced that...

  • Press Releases

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California

  • Press Releases

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

  • Press Releases

San Diego, CA, and Bergisch Gladbach, Germany – September 15,

  • Press Releases

South San Francisco, CA, June 25, 2026 – The California

  • Press Releases

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

  • Press Releases